BioStock: Chordate could contribute to migraine care in Sweden

Over 1 million Swedes suffer from migraine and the majority of them are women. Migraine care is considered to be inadequate and many are undiagnosed. In addition, today’s drugs are often associated with a decreasing treatment effect and side effects. Sweden’s new government wants to see a change and has thus decided to place greater emphasis on care for migraines and other women’s diseases, according to the recent Statement of Government Policy. Chordate Medical’s CEO Anders Weilandt says that they want to contribute to this with K.O.S, a drug-free and preventive migraine treatment.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/10/chordate-could-contribute-to-migraine-care-in-sweden/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/